199 related articles for article (PubMed ID: 10421547)
1. Maximizing therapeutic gain with gemcitabine and fractionated radiation.
Mason KA; Milas L; Hunter NR; Elshaikh M; Buchmiller L; Kishi K; Hittelman K; Ang KK
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1125-35. PubMed ID: 10421547
[TBL] [Abstract][Full Text] [Related]
2. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
Mason KA; Kishi K; Hunter N; Buchmiller L; Akimoto T; Komaki R; Milas L
Clin Cancer Res; 1999 Dec; 5(12):4191-8. PubMed ID: 10632360
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of tumor radioresponse in vivo by gemcitabine.
Milas L; Fujii T; Hunter N; Elshaikh M; Mason K; Plunkett W; Ang KK; Hittelman W
Cancer Res; 1999 Jan; 59(1):107-14. PubMed ID: 9892194
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse.
Mason KA; Hunter NR; Raju U; Ariga H; Husain A; Valdecanas D; Neal R; Ang KK; Milas L
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1181-9. PubMed ID: 15234054
[TBL] [Abstract][Full Text] [Related]
5. Combined use of gemcitabine and radiation in mice.
Cividalli A; Livdi E; Ceciarelli F; Fontana G; Altavista P; Cruciani G; Danesi DT
Anticancer Res; 2001; 21(1A):307-12. PubMed ID: 11299753
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin.
Kirichenko AV; Rich TA; Newman RA; Travis EL
Cancer Res; 1997 May; 57(10):1929-33. PubMed ID: 9157987
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).
Fields MT; Eisbruch A; Normolle D; Orfali A; Davis MA; Pu AT; Lawrence TS
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):785-91. PubMed ID: 10837965
[TBL] [Abstract][Full Text] [Related]
8. WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment.
Phan TP; Crane CH; Janjan NA; Vrdoljak E; Milas L; Mason KA
Int J Pancreatol; 2001; 29(1):19-23. PubMed ID: 11558629
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model.
Joschko MA; Webster LK; Groves J; Yuen K; Palatsides M; Ball DL; Millward MJ
Radiat Oncol Investig; 1997; 5(2):62-71. PubMed ID: 9303059
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma.
Milas L; Saito Y; Hunter N; Milross CG; Mason KA
Radiother Oncol; 1996 Aug; 40(2):163-70. PubMed ID: 8884971
[TBL] [Abstract][Full Text] [Related]
11. Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration.
Kirichenko AV; Rich TA
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):659-64. PubMed ID: 10348297
[TBL] [Abstract][Full Text] [Related]
12. Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa.
Mason KA; Milas L; Peters LJ
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1381-9. PubMed ID: 7635778
[TBL] [Abstract][Full Text] [Related]
13. Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability.
Milas L; Mason KA; Hunter N; Li C; Wallace S
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):707-12. PubMed ID: 12573758
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
Grégoire V; Hunter N; Milas L; Brock WA; Plunkett W; Hittelman WN
Cancer Res; 1994 Jan; 54(2):468-74. PubMed ID: 8275483
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel enhances tumor radioresponse in vivo.
Mason KA; Hunter NR; Milas M; Abbruzzese JL; Milas L
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2431-8. PubMed ID: 9815644
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma.
Lin LL; Picus J; Drebin JA; Linehan DC; Solis J; Strasberg SM; Tan B; Thorstad WL; Myerson R
Am J Clin Oncol; 2005 Jun; 28(3):234-41. PubMed ID: 15923794
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.
Grégoire V; Beauduin M; Rosier JF; De Coster B; Bruniaux M; Octave-Prignot M; Scalliet P
Br J Cancer; 1997; 76(10):1315-21. PubMed ID: 9374377
[TBL] [Abstract][Full Text] [Related]
18. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation.
Grégoire V; Hunter N; Brock WA; Milas L; Plunkett W; Hittelman WN
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):363-71. PubMed ID: 7928463
[TBL] [Abstract][Full Text] [Related]
20. Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm.
Regine WF; Hanna N; Garofalo MC; Doyle A; Arnold S; Kataria R; Sims J; Tan M; Mohiuddin M
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):172-7. PubMed ID: 17276612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
